专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

EP2647384B1 IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH alpha CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V alpha-J alpha , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS 有权
公开(公告)号：EP2647384B1
公开(公告)日：2018-05-23
申请号：EP11844377.9
申请日：2011-12-02
申请人： Riken
发明人： TANIGUCHI, Masaru , KOSEKI, Haruhiko , WATARAI, Hiroshi , FUJII, Shin-ichiro
IPC分类号： A61K35/17 , A61K31/7028 , A61P31/00 , A61P35/00 , A61P37/06 , A61P37/08 , A61K45/06 , C07K14/725 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/7028 , A61K45/06 , C07K14/7051 , C12N5/0646 , C12N15/85 , A61K2300/00
摘要： The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the ±-chain region of the T cell receptor gene rearranged to uniform V±-J± in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the ±-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V±-J±. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

12. 发明授权

EP3119800B1 GLYCOPEPTIDE DERIVATIVES FOR THE PRESERVATION AND PROTECTION OF BIOLOGICAL MATERIALS AND MICROORGANISMS 有权
标题翻译：用于保护和保护生物材料和微生物的糖肽衍生物
公开(公告)号：EP3119800B1
公开(公告)日：2018-02-28
申请号：EP15711716.9
申请日：2015-03-17
申请人： Tfchem
发明人： DELIENCOURT-GODEFROY, Géraldine , MARTIN, Thibaut
IPC分类号： C07H7/02 , C07H15/04 , C07H15/18 , A61K8/64 , A61Q19/00 , A61K31/7028 , A61Q19/08 , C07K5/06 , C07K5/062
CPC分类号： C07K9/001 , A01N1/0226 , A61K8/64 , A61K8/69 , A61K31/7028 , A61K38/14 , A61Q19/00 , A61Q19/08 , C07H7/02 , C07H15/04 , C07H15/18 , C07K5/06052 , C07K5/06191
摘要： The present invention relates to a compound of the following formula (I): in which at least one and only one group chosen among R5, R6 and R7 is a group of the following formula: The present invention relates also to uses thereof for preservation and/or protection and/or regeneration of biological materials and or microorganisms and for cosmetic or dermato logical applications such as anti-aging, skin protection and skin regeneration; to culture, storage and/or preservation media comprising such a compound; to cosmetic or dermato logical compositions comprising such a compound; to processes for preparing such a compound; and to synthesis intermediates.

13. 发明公开

EP3269385A1 PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION 审中-公开
标题翻译：肺炎球菌多糖 - 蛋白质共轭体组合物
公开(公告)号：EP3269385A1
公开(公告)日：2018-01-17
申请号：EP16179133.0
申请日：2016-07-12
申请人： Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. , Vaxxilon AG
发明人： SEEBERGER, Peter H.
IPC分类号： A61K39/09 , A61K31/7028
CPC分类号： A61K39/092 , A61K31/7028 , A61K2039/6037 , A61K2039/62
摘要： The present invention relates to immunogenic compositions comprising a conjugate of a saccharide from Streptococcus pneumoniae serotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM 197 carrier protein, or a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide from Streptococcus pneumoniae serotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide from Streptococcus pneumoniae serotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by Streptococcus pneumoniae serotype 8.
摘要翻译：本发明涉及免疫原性组合物，其包含来自肺炎链球菌血清型8和载体蛋白的糖的缀合物，以及由来自肺炎链球菌血清型1,3,4,5,6A，6B，7F，9V， 14，18C，19A，19F和23F单独缀合至CRM197载体蛋白的混合物，或由来自肺炎链球菌血清型1,4,5,6B，7F，9V，14,18C，19F和23F的荚膜多糖组成的混合物，载体蛋白，其中来自肺炎链球菌血清型1,4,5,6B，7F，9V，14和23F的荚膜多糖分别缀合至蛋白D，来自肺炎链球菌血清型18C的荚膜多糖缀合至破伤风类毒素并且囊膜来自肺炎链球菌血清型19F的多糖与白喉类毒素缀合。所述组合物可用于预防和/或治疗由肺炎链球菌血清型8引起的疾病。

14. 发明授权

EP2575768B1 AQUEOUS DISPERSION COMPRISING GALACTOLIPIDS AND METHOD FOR PRODUCTION THEREOF 有权转让
标题翻译：包含乳胶脂的水分散体及其制备方法
公开(公告)号：EP2575768B1
公开(公告)日：2017-12-13
申请号：EP11786992.5
申请日：2011-05-24
申请人： Swedish Oat Fiber AB
发明人： LARSSON, Kåre , HÄRRÖD, Magnus
IPC分类号： A61K9/127 , A23D7/04 , A61K36/899 , A23D7/005 , A61K47/44
CPC分类号： A23L1/3006 , A23D7/0053 , A23D7/0056 , A61K8/0295 , A61K8/04 , A61K8/062 , A61K8/14 , A61K8/92 , A61K8/922 , A61K9/10 , A61K9/107 , A61K9/127 , A61K9/1272 , A61K9/1274 , A61K9/1277 , A61K31/7028 , A61K36/899 , A61K47/44 , A61K2800/10 , A61Q19/00
摘要： A method for preparing a dispersion of polar lipids in an ethanol-water mixture, the polar lipids including galactolipids. An oil containing polar lipids including galactolipids is diluted using a first ethanol-water mixture having an ethanol concentration close to the critical polarity, wherein upon dilution the polar lipids form a lamellar liquid-crystalline phase, without first forming a hexagonal HII-phase. The invention also refers to an oil obtained by evaporating ethanol and water from the dispersion. The invention further refers to aqueous colloidal dispersions of polar lipids including galactolipids, to an oil containing polar lipids including galactolipids and to pharmaceutical, cosmetic and food compositions including such dispersions and/or oil.

15. 发明授权

EP2521554B1 MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS 有权转让
标题翻译：用于防止和治疗病毒感染的材料和方法
公开(公告)号：EP2521554B1
公开(公告)日：2017-11-22
申请号：EP10840657.0
申请日：2010-12-30
申请人： BAGI Research Limited , Versitech Limited
发明人： LAU, Allan, Sik-Yin , YANG, Lai, Hung, Cindy , LAW, Anna, Hing-Yee
IPC分类号： A61K31/7048 , A61K31/7032 , A61K31/215 , A61K31/192 , A61K36/899 , A61K36/634 , A61K36/538 , A61K36/534 , A61K36/484 , A61K36/48 , A61K36/35 , A61K36/34 , A61K36/28 , A61P31/16
CPC分类号： A61K31/7028 , A61K31/192 , A61K31/215 , A61K36/33 , A61K36/355 , A61K36/48 , A61K36/484 , A61K36/534 , A61K36/538 , A61K36/634 , A61K45/06 , Y02A50/463 , A61K2300/00
摘要： The subject invention provides a novel and advantageous method for preventing and treating viral infection. Specifically exemplified herein are therapeutic uses of forsythoside A and jacaranone, compounds isolated from traditional Chinese medicinal material such as Fructus forsythiae (Lian Qiao). Also provided is use of a Yin Qiao San composition for preventing and treating viral infection.

16. 发明公开

EP3242883A1 LIPID A MIMICS, METHODS OF PREPARATION, AND USES THEREOF 无效
标题翻译：脂质模拟物，制备方法及其用途
公开(公告)号：EP3242883A1
公开(公告)日：2017-11-15
申请号：EP15876412.6
申请日：2015-12-11
申请人： ImmunoVaccine Technologies Inc.
发明人： JIANG, Zi-hua , LEWICKY, Jordan David , WEIR, Genevieve Mary , RAJAGOPALAN, Rajkannan , SAMMATUR, Leeladhar , STANFORD, Marianne Michelle , MANSOUR, Marc
IPC分类号： C07H15/18 , A61K31/7028 , A61K39/39 , A61P25/30 , A61P31/00 , A61P35/00 , A61P37/02 , C07H13/06
CPC分类号： C07H11/04 , A61K31/7028 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/55555 , A61K2039/55572 , A61K2039/585 , A61K2039/6031 , A61K2039/6037 , A61K2039/605 , C07H15/18 , C12N7/00 , C12N2710/20034 , C12N2710/20071 , Y02A50/412
摘要： The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.

17. 发明授权

EP2332947B1 SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE 有权
标题翻译：（2S，3R，4R，5S，6R）-2-（4-氯-3-（4-乙氧基苄基）苯基）-6-（甲硫基）四氢-2H-吡喃-3,4,5-三醇的固体形式及其使用方法
公开(公告)号：EP2332947B1
公开(公告)日：2017-11-01
申请号：EP11155100.8
申请日：2009-07-15
申请人： Lexicon Pharmaceuticals, Inc.
发明人： De Paul, Susan Margaret , Perlberg, Anett , Zhao, Matthew Mangzhu
IPC分类号： C07H15/14 , A61K31/70 , A61P3/10
CPC分类号： C07H15/14 , A61K31/7028 , A61K31/7034 , C07H7/04

18. 发明公开

EP3090728A4 ORAL COMPOSITION 有权
标题翻译： ORALE ZUSAMMENSETZUNG
公开(公告)号：EP3090728A4
公开(公告)日：2017-08-09
申请号：EP13900001
申请日：2013-12-27
申请人： KAO CORP
发明人： OGIHARA AYA , ITANO MORIHIDE
IPC分类号： A61K8/60 , A61K8/41 , A61K8/43 , A61K8/49 , A61K9/00 , A61K9/08 , A61K31/4425 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/44 , A61Q11/00
CPC分类号： A61K8/604 , A61K8/416 , A61K8/43 , A61K8/4926 , A61K8/60 , A61K8/922 , A61K9/0053 , A61K9/08 , A61K31/4425 , A61K31/7028 , A61K47/10 , A61K47/14 , A61K47/186 , A61K47/26 , A61K47/32 , A61K47/44 , A61K2800/592 , A61Q11/00 , C07H15/04 , A61K2300/00
摘要： The present invention relates to an oral composition having an enhanced solubility of an alkyl galactoside while holding an inhibiting effect on coaggregation of the alkyl galactoside well. The present invention provides an oral composition comprising the following components: (A) 0.001 mass% or more and 1 mass% or less of a compound represented by the following formula (I): wherein R is an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G is a galactose residue, E is a hydrogen atom or a methyl group, m is an integer of 0 to 200, and n is an integer of 1 to 30; (B) 0.001 mass% or more and 0.1 mass% or less of a cationic bactericide; and (C) 35 mass% or more of water.
摘要翻译：本发明涉及一种口服组合物，其具有增强的烷基半乳糖苷溶解度，同时对烷基半乳糖苷的共聚集作用具有良好的抑制作用。本发明提供含有下述成分的口腔用组合物：（A）下述式（I）所示的化合物0.001质量％以上1质量％以下，其中，R为可以具有取代基的直链状或支链状的烷基，碳原子数8〜18，G为半乳糖残基，E为氢原子或甲基，m为0〜200的整数，n为1〜30的整数。（B）阳离子性杀菌剂为0.001质量％以上且0.1质量％以下，和（C）35质量％以上的水。

19. 发明公开

EP3046537A4 PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE 有权转让
标题翻译：碳水化合物可用于治疗性应用的药物研制
公开(公告)号：EP3046537A4
公开(公告)日：2017-04-19
申请号：EP14851464
申请日：2014-09-16
申请人： GLYCOMINE INC
发明人： RAFALKO AGNES , CHERNENKO TATYANA
IPC分类号： A61K9/00 , A61K9/127 , A61K31/00
CPC分类号： A61K9/1271 , A61K9/127 , A61K31/7028
摘要： The disclosure provides methods for preparation of carbohydrate replacement therapies (CRT) that include nanocarriers of carbohydrates and glycolipids for pharmaceutical delivery to cell interior, endoplasmic reticulum, and Golgi for treating CDG type I and CDG type II diseases as well as other metabolic disorders.

20. 发明公开

EP2968215A4 THIOSACCHARIDE MUCOLYTIC AGENTS 有权转让
标题翻译： THIOSACCHARID，黏液溶解剂
公开(公告)号：EP2968215A4
公开(公告)日：2017-03-01
申请号：EP14767630
申请日：2014-03-14
申请人： UNIV CALIFORNIA , UNIV DUBLIN
发明人： OSCARSON STEFAN , FAHY JOHN VINCENT , YUAN SHAOPENG , CARRINGTON STEPHEN
IPC分类号： A61K31/10 , A61K31/70 , A61K31/7016 , A61K31/702 , A61K31/7028 , A61P11/12 , C07D309/10 , C07H5/04 , C07H13/04 , C07H15/04
CPC分类号： C07H15/04 , A61K31/70 , A61K31/7016 , A61K31/702 , A61K31/7028 , C07D309/10 , C07H5/04 , C07H13/04
摘要： There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式